Media

Doctrin appoints Unn Hellberg as new CEO

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

Kivu Bioscience Appoints Julie Hambleton, M.D., to its Board of Directors

Aro Biotherapeutics to Present Clinical Update from its Pompe Disease Program at the 22nd Annual WORLD Symposium

Oncopeptides announces Q4 2025 sales and updates cash-flow expectations

Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors

Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital

Vicore Pharma to present at the 44th Annual J.P. Morgan Healthcare Conference